G ene therapy is a medical intervention to alter the genetic program of cells for therapeutic purposes.' The endothelium of arteries and veins represents an important potential target for gene therapy by virtue of its large surface area and proximity to the circulation.2-14 If genes can be transferred to the vascular endothelium, it should be possible to modify the function and integrity of the blood vessel wall and to deliver therapeutic proteins into the circulation. In this context, gene transfer to the endothelium may be applicable to a variety of inherited and acquired diseases.
Theoretically, two strategies could be used to achieve the goal of gene therapy using the endothelium in vivo.
First, the gene can be transferred into endothelial cells in vitro, followed by reintroduction of the modified cells into the vessel wall of the recipient.2-5 Second, the gene can be transferred in vivo directly into the vessel wall.7,"16,3-1 Although the in vitro approach is readily achieved by a variety of approaches, the in vivo strategy has a major technical hurdle based on the inherent biology of the endothelium in its resting state in vivo. In this regard, endothelial cells replicate slowly, limiting the use of gene transfer vectors that depend on cell proliferation to express the exogenous gene. '17"8 The replication-deficient recombinant adenovirus (Ad), which does not require host cell proliferation to express the exogenous gene, offers a potential solution to this problem. In a recent study, we demonstrated that Ad vectors will mediate transfer of genes to intact human vessels ex vivo, with a high level of expression of the transferred gene in the endothelium. 19 Other useful characteristics of Ad vectors are as follows: 1) They can be manipulated to accommodate exogenous genes of at least 7.5 kb. 2) Live Ads have been used safely as human vaccines in more than 5 million individuals. 3) There is no known association of human malignancy with Ad infection.20-24 Human Ad vectors have been approved by the National Institutes of Health recombinant DNA advisory committee for human gene transfer trials to treat the respiratory manifestations of cystic fibrosis. 25 With the knowledge that human endothelial cells are susceptible to in vitro gene transfer with Ad vectors, the present study is directed at evaluating the feasibility of Ad-mediated gene transfer in vivo in normal intact vessels. To In Vivo Gene Transfer
The in vivo study was carried out with female and male sheep weighing [20] [21] [22] [23] [24] [25] kg (mixed Rambouillet, Dorset, Suffolk breed; 4-6 months old). Gene transfer was attempted in a total of 26 sheep. Two animals died and were not evaluated: one during surgery of a cardiac arrhythmia and one of aspiration pneumonia at 1 day. Twenty-four sheep were evaluated for administration of the Ad vectors into jugular veins, and 22 were evaluated for administration into carotid arteries. The administrations of Ad vectors to the lumen of veins and arteries were performed under general anesthesia and sterile surgical conditions. Anesthesia was induced with intravenous sodium pentobarbital (25 mg/kg) and diazepam (10 mg) and maintained with 1-2% isoflurane with oxygen via an endotracheal tube and a volume-cycled ventilator. Bilateral longitudinal cervical incisions exposed the right and left external jugular veins and common carotid arteries. The periadventitial tissues of the common carotid arteries were infiltrated with papaverine (30 mg/ml, 0.5-1 ml) and lidocaine hydrochloride (10 mg/ml, 0.5-1 ml) to prevent vasospasm. All branches of both arteries and veins, between and including the superior and inferior laryngeal branches, were ligated and divided. Bovine lung sodium heparin (300 units/kg) was injected intravenously for systemic anticoagulation while the vessels were occluded. The vessels were encircled with silastic tourniquets, isolating a 5-cm segment of each. Blood was evacuated from the vessels, and the medium containing the Ad vector (1-4x1010 pfu in 800 gul into the external jugular veins and 0.5-3 x 1010 pfu in 400 gl into the carotid arteries) was introduced by direct injection into the lumen of the occluded vessel segment. For each animal, the lumen of the right jugular vein and/or carotid artery was injected with Ad.RSVPgal or Ad-a,AT, while the lumen of the contralateral vessel was used as a control and was injected with AdCFTR. After 15 minutes of incubation (a time determined by preliminary in vitro studies, see "Results"), the medium containing the remaining Ad vector inside the occluded vessel segment was aspirated, the tourniquets were removed, and circulation was restored. To aid in identification of the segments of the vessels exposed to the Ad vectors, the regions of the vessels that had been exposed to the vectors were delineated by suture markers placed circumferentially. The cervical incisions were closed, and the animals were allowed to recover. Prophylactic antibiotics, gentamicin (3 mg/kg) and penicillin G (9 x 105 units), were administered twice daily for 3 days.
The vessels were harvested 1-28 days later under general anesthesia as described above. After exposure of the vessels, the animals received systemic heparin. The carotid arteries and external jugular veins were excised before euthanasia. To evaluate the specificity of the local administration of the vectors, in selected animals, tissue samples of cervical muscle, thyroid, liver, lung, heart, spleen, brain, both kidneys, and gonads were excised after death.
Evaluation of Gene Transfer and Expression
To evaluate in vivo gene transfer and expression at the histological level, 3 To evaluate the feasibility of in vivo gene transfer with direct intraluminal exposure of the Ad vectors in blood vessels and to identify the cell types expressing the exogenous gene, the Ad vector containing the lacZ gene (and as a control, AdCFTR) was administered into the lumen of jugular veins, and fl-gal expression in the vein was evaluated 72 hours later. After administration of AdCFTR, X-Gal staining revealed no blue coloration and thus no l3-gal activity (Figures 2A and 2B ). In contrast, after administration of Ad.RSVflgal, X-Gal staining showed extensive blue coloration of the interior of the portion of the vessel exposed to the vector, indicative of fl-gal activity in cells lining the lumen (Figures 2D and 2E ). Microscopic examination of the veins showed normal morphology after exposure to either AdCFTR and Ad.RSVflgal. Strikingly, there was fl-gal activity only in the veins exposed to the Ad.RSVflgal vector, and the /3-gal expression was limited to the endothelial cells (Figures 2C and 2F) .
In the carotid arteries exposed to the Ad vectors, the results were similar. After administration of AdCFTR, X-Gal staining revealed no blue coloration and thus no fl-gal activity ( Figures 3A and 3B ). In contrast, after administration of Ad.RSV,/gal, X-Gal staining showed extensive blue color of the interior of the vessel exposed to the vector, indicative of /3-gal activity in cells lining the lumen (Figures 3D and 3E tion of the arteries showed normal morphology after exposure to either AdCFTR or Ad.RSV,3gal. As with the veins, there was fl-gal expression only in the arteries exposed to Ad.RSVflgal, and the fl-gal expression was limited to the endothelial cells ( Figures 3C and 3F) .
In three sheep in which veins and arteries were exposed to Ad.RSVflgal in vivo, tissues from cervical muscle, liver, lung, heart, spleen, brain, both kidneys, both gonads, and thyroid (used as a positive control) were excised after death and stained with X-Gal in parallel with the vessels. None of these tissues showed any fl-gal activity, except the thyroid, as expected, which showed light cytoplasmic blue coloration that was due to the presence of endogenous /3-gal (not shown).
After in vivo exposure to Ad-alAT, the endothelial cells in both jugular veins and carotid arteries expressed the human alAT cDNA. Northern analysis was performed with an a1AT cDNA probe, and no a1AT mRNA transcripts were observed in veins 1 day after exposure to AdCFTR (Figure 4, lane 1) . In contrast, human alAT mRNA transcripts of the expected size were detected in veins exposed to Ad-alAT at 1, 7, and 14 days after administration of the vector (lanes 2-4) . veins exposed to Ad-alAT at 1, 7, and 14 days after exposure to the vector (lanes 7-9). As with the veins, no alAT mRNA transcripts could be detected 28 days after exposure to Ad-a1AT (lane 10). Control y-actin mRNA transcripts were at similar levels in all samples (lanes [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 0 t 0 2 _ W e @ ' < s 5 < . a 5 a 4 : ? > P ; -g i i : e r w * r . : 8 8 -. ---, ! . , i z ; * * b .
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. K s F ; ; X a * @ P . . . . . . . X ; , > 1 . . e * t 6 9 S & o / . . . . . . . . . minutes, there is effective transfer and easily detectable expression of the exogenous gene contained within the vector for at least 2 weeks, suggesting that Ad-mediated gene transfer could be used for a variety of potential therapies for human diseases. The data also suggest that endothelial cells have receptors for Ad, although direct quantification of receptor number and avidity have not been made. These results are consistent with our previous study,19 in which the same Ad vectors were used to transfer exogenous genes to human umbilical vein endothelial cells in vitro and to the intact umbilical vein ex vivo and in which the peak of expression of the transferred gene was also at 7 days. In the present study, we could not detect by ELISA human alAT in the serum of the sheep that received Ad-a1AT 1 day after administration of Ad-alAT in the jugular vein, likely because of the dilution of the secreted alAT into the blood mass of the sheep (approximately 2 1) and the detection threshold of the ELISA. 2' There are a number of advantages of Ad vectors over other approaches to in vivo gene transfer to blood vessels. First, although not evaluated in this study, it is likely that the Ad DNA is not integrated in the genome of the target cell.22,23 This has advantages for gene therapy in that insertional mutagenesis is not a concern, and it may provide flexibility for dosing therapeutic genes in acute acquired diseases. Second, the Ad does not require target cell proliferation to express the exogenous gene, in contrast to retrovirus vectors in which target cell replication is required. In this regard, because the endothelium replicates very slowly in vivo, to achieve efficient gene transfer, retrovirus vectors necessitate local injury (such as with an intravascular balloon or high injection pressure) to promote endothe- 
